Apellis Pharmaceuticals’ APL-2 Receives Fast Track Designation from FDA for the Treatment of Patients with Geographic Atrophy
In All, PortfolioCRESTWOOD, Ky., and WALTHAM, Mass., – Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track…